Milton Rossman, M.D.

Professor of Medicine

University of Pennsylvania Medical Center
Pulmonary, Allergy & Critical Care Division
834 West Gates Building
3400 Spruce Street
Philadelphia, PA 19104
tel.: (215) 573-9890
fax: (215) 573-4469
email: rossmanm@mail.med.upenn.edu

Education:

MD: Jefferson Medical College

Internship: University of Pennsylvania Division of Philadelphia General Hospital

Public Health Service: Foreign Quaranteen and Tuberculosis Division, Center for Disease Control

Residency: University Hospitals of Cleveland

Fellowship: Hospital of the University of Pennsylvania

Research Program:

Pulmonary granulomatous disorders

Granulomatous Lung Inflammation:

Identification on a cellular and molecular level of the mechanisms responsible for granulomatous inflammation in the lung. Studies are currently underway to identify cytokine profile of lung cells involved in chronic beryllium diseas and, sarcoidosis. In addition, the class II molecules that present these antigens are being characterized molecularly. Understanding of the specific molecules involved in granulomatous inflammation should allow the development of new therapeutic strategies for these disorders. In addition, Dr. Rossman's laboratory has participated in 2 NIH sponsored collaborative studies of sarcoidosis. Studies are currently underway investigating gene-environment interactions in sarcoidosis and chronic beryllium disease. Dr. Rossman's laboratory is one of 5 laboratories in the country certified to perform beryllium stimulated lymphocyte proliferation assays.

Drug Trials in Interstitial Lung Disease. Dr. Rossman is a PI on three active placebo controlled trials in interstitial lung disease. These include remecade (infliximab) for chronic beryllium disesase, and pirfenidone and Traclear for UIP. In addition, Dr. Rossman is the PI for Univ. of PA site of the DOE’s beryllium bio-repository and DNA and plasma core.

Clinical Interest:

Dr. Rossman is the Director of the Pulmonary Bronchoscopy Laboratory and the Director of the Interstitial and Sarcoidosis Lung Disease Programs. He is an expert in tuberculosis, sarcoidosis, chronic beryllium disease and the idiopathic interstitial pneumonias including idiopathic pulmonary fibrosis.

Rossman M, Newman L, Baughman R, Teirstein A, Weinberger S, Miller Jr W, Sands B. A Double-blinded, randominzed, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis vasculitis and diffuse lung diseases. Sarcoidosis Vasculitis and Diffuse Lung Disease 2006; 23:

Baughman RP, Judson MA, Teirstein A, Yeager H, Rossman M, Knatterud GL, Thompson B. Presenting characteristics as predictors of duration of treatment in sarcoidosis. QJM. 99:307-15, 2006.

Rosenman K, Hertzberg V, Rice C, Reilly MJ, Aronchick J, Parker JE, Regovich J, Rossman M. Chronic beryllium disease and sensitization at a beryllium processing facility. Environ Health Perspect. 2005 Oct;113(10):1366-72.

Schuler CR, Kent MS, Deubner DC, Berakis MT, McCawley M, Henneberger PK, Rossman MD, Kreiss K. Process-related risk of beryllium sensitization and disease in a copper-beryllium alloy facility. Am J Ind Med. 2005 Mar;47(3):195-205.

Newman LS, Rose CS, Bresnitz EA, Rossman MD, Barnard J, Frederick M, Terrin ML, Weinberger SE, Moller DR, McLennan G, Hunninghake G, DePalo L, Baughman RP, Iannuzzi MC, Judson MA, Knatterud,GL, Thompson BW, Teirstein AS, Yeager HJr, Johns CJ, Rabin DL, Rybicki BA, Cherniack R, and the ACCESS Research Group. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med. 2004 Dec 15;170(12):1324-30

Rossman MD. Thompson B, Frederick M, Maliarik M, Iannuzzi MC, Rybicki BA, Pandey JP, Newman LS, Magira E, Beznik-Cizman B, Monos D, and the ACCESS Group. HLA-DRB1*1101: A Significant Risk Factor for Sarcoidosis in Blacks and Whites. Am. J. Human Genetics. 73:720-735,2003.